Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carlos J C Andrade"'
Autor:
Fauze Maluf-Filho, João Nunes de Matos Neto, Nils Gunnar Skare, Hezio Jadir Fernandes Júnior, Maria Nunes Álvares, J.G.M. Segalla, Bruno de Araújo Lima França, Ismael Dale Cotrim Guerreiro da Silva, Carlos J C Andrade, Auro Del Giglio, Giuliano Santos Borges, Gustavo Girotto, Nora Manoukian Forones, Sergio J Azevedo, Nicolas Lazaretti, Daniel Grabarz, Gilberto de Castro Junior, Celio Kussumoto, José Luiz Pedrini
Publikováno v:
European journal of cancer (Oxford, England : 1990). 88
Purpose Chemoradiotherapy is the standard treatment for patients with inoperable locally advanced oesophageal cancer. We sought to assess the safety and efficacy of chemoradiation combined with nimotuzumab, a humanised antibody directed against epide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b385859af9cce7731bc13afa0a99b9
https://pubmed.ncbi.nlm.nih.gov/29179134
https://pubmed.ncbi.nlm.nih.gov/29179134
Autor:
Bruno dos Santos Vilhena Pereira, Rafael Coelho, Roberto de Almeida Gil, Ana Paula Stramosk, Mariana Ribeiro Monteiro, Márcia Silveira Graudenz, Pedro Duarte Abreu, Cristiano Guedes Duque, Mariana Bruno Siqueira, Carlos J C Andrade, Alexandre de Mendonca Palladino
Publikováno v:
Journal of Clinical Oncology. 35:e15511-e15511
e15511 Background: Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide.Classic regimens in first line setting for advanced GC combine platinum compounds and fluoropirimidines ± antracyclines or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::708ece004654911600578f70210f7364
https://doi.org/10.1200/jco.2017.35.15_suppl.e15511
https://doi.org/10.1200/jco.2017.35.15_suppl.e15511
Autor:
M.N. Álvares, Gustavo Girotto, Carlos J C Andrade, Nicolas Lazaretti, B. Franca, H. Fernandes, Nils Gunnar Skare, D. Grabarz, J.G.M. Segalla, J.L. Pedrini, J.N.D. Matos Neto, L.P.D.G. Neusquen, Giuliano Santos Borges, C. Kussumoto, G. De Castro, A. Del Giglio, I. Dale, Nora Manoukian Forones, Sergio J Azevedo
Publikováno v:
Annals of Oncology. 25:iv218
Aim: NICE trial showed that combination of chemoradiation and nimotuzumab, a humanized antibody against EGFR, is safe and appears to increase the combined complete response (cCR) rate, defined as endoscopic and/or pathologic CR, in pts with locally a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b226ab70429333b8a2b3ad8e7ddf713d
https://doi.org/10.1093/annonc/mdu334.23
https://doi.org/10.1093/annonc/mdu334.23
Autor:
Gilberto de Castro, Fauze Maluf Filho, Nils Gunnar Skare, Ismael Dale Cotrim Guerreiro da Silva, Sergio J Azevedo, Cassiano Ricardo de Oliveira Berto, J.G.M. Segalla, Carlos J C Andrade, Lucienne Pereira Del Grossi Neusquen
Publikováno v:
Journal of Clinical Oncology. 32:4078-4078
4078 Background: Chemoradiation is the standard therapy for patients (pts) with inoperable LAEC. We sought to assess the safety and activity of chemoradiation combined with nimotuzumab, a humanized...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14a0736a788d9ee67cf7067a09b68c6e
https://doi.org/10.1200/jco.2014.32.15_suppl.4078
https://doi.org/10.1200/jco.2014.32.15_suppl.4078
Autor:
Nise Hitomi Yamaguchi, Ingrid A. Mayer, Auro del Giglio, H. Cardoso, Artur Malzyner, Andre M. Murad, Carlos J C Andrade
Publikováno v:
Journal of Clinical Oncology. 22:3086-3086
3086 Background: Gefitinib (‘Iressa’, ZD1839) is an EGFR-TKI (tyrosine kinase inhibitor) and celecoxib is a COX2 inhibitor with anti-inflammatory, anti-angiogenic, and anti-proliferative properties. In the early development of gefitinib, anecdota
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::569788816e92339463244d06973753f9
https://doi.org/10.1200/jco.2004.22.90140.3086
https://doi.org/10.1200/jco.2004.22.90140.3086